Follow us on Twitter
This page is updated frequently with new Anergy-related patents. Subscribe to the Anergy RSS feed to automatically get the update: related Anergy RSS feeds.
Subscribe to updates on this page: Anergy RSS
|| List of recent Anergy-related patents
|Method for inducing immune tolerance using viable polymer-modified allogeneic leukocytes|
This invention relates to cellular-based therapies for increasing the level of regulatory t cells (treg) and/or decreasing the level of pro-inflammatory t cells (th17) to induce anergy or immune tolerance. To provide these therapeutic effects, two allogeneic leukocyte populations are contacted (in vivo, in vitro or ex vivo) and one of these leukocyte population is modified to bear on its surface a low-immunogenic biocompatible polymer so as to prevent pro-inflammatory allo-recognition.
|Serum amyloid a (saa) overrides regulatory t cells (treg) anergy|
Methods and compositions are provided for inducing the proliferation of regulatory t cells. These methods find a number of uses, including, for example, treating autoimmune and rheumatoid diseases.
|Mucin antigen vaccine|
Provided are expression vectors for generating an immune response to a mucin. The vectors comprise a transcription unit encoding a secretable polypeptide, the polypeptide comprising a secretory signal, a mucin antigen and cd40 ligand.
|Induction of tumor immunity by variants of folate binding protein|
The present invention is directed to variants of antigens comprising folate binding protein epitopes as a composition associated with providing immunity against a tumor in an individual. The variant is effective in inducing cytotoxic t-lymphocytes but preferably not to the extent that they become sensitive to silencing by elimination, such as by apoptosis, or by anergy, as in unresponsiveness..
|Simultaneous inhibition of pd-l1/pd-l2|
Methods and compositions for treating an infection or disease that results from (1) failure to elicit rapid t cell mediated responses, (2) induction of t cell exhaustion, t cell anergy or both, or (3) failure to activate monocytes, macrophages, dendritic cells and/or other apcs, for example, as required to kill intracellular pathogens. The method and compositions solve the problem of undesired t cell inhibition by simultaneously inhibiting the pd-1 ligands, pd-l1 and pd-l2.
Popular terms: [SEARCH]
Anergy topics: Immune Response, Expression Vector, Cancer Cells, Cancer Cell, Transcription, Polypeptide, Lymphocyte, Intracellular, Immune System, Macrophage, Dendritic Cell, Dissociation, Antagonist, Type I Diabetes, Rheumatoid Factor
Follow us on Twitter
This listing is a sample listing of patents related to Anergy for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Anergy with additional patents listed. Browse our RSS directory or Search for other possible listings.